Holen Sie sich die Stockscreener-App
60.28
1.23%
0.73
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
CG Oncology touts cretostimogene data, BLA progress in bladder cancer push - MSN
Midday Stock Roundup: CG Oncology gains - Orange County Business Journal
CG Oncology, Inc. (CGON) upgraded to buy: Here's what you should know - MSN
CG Oncology, Inc. (CGON) reports Q1 loss, tops revenue estimates - MSN
CG Oncology (CGON) Valuation Check As Cretostimogene Nears Phase 3 Data And Planned Regulatory Filing - Sahm
TD Asset Management Inc Grows Stock Position in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology, Inc. $CGON Shares Purchased by Clearbridge Investments LLC - MarketBeat
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead - MarketBeat
CGON: Pivotal NMIBC trial results and regulatory filings position cretostimogene for first approval - TradingView
CenterBook Partners LP Sells 326,116 Shares of CG Oncology, Inc. $CGON - MarketBeat
CG Oncology (NASDAQ: CGON) investors back directors, EY and pay plan - Stock Titan
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push - MarketBeat
CGON Technical Analysis & Stock Price Forecast - Intellectia AI
CGON Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CG Oncology (CGON) director receives 9,354 stock options at $56.09 strike - Stock Titan
CG Oncology (NASDAQ: CGON) director receives 9,354 stock options at $56.09 exercise price - Stock Titan
[Form 4] CG Oncology, Inc. Insider Trading Activity - Stock Titan
CG Oncology (NASDAQ: CGON) director receives 9,354-share stock option grant - Stock Titan
CG Oncology (NASDAQ: CGON) director receives grant of 9,354 stock options at $56.09 - Stock Titan
CG Oncology set to report earnings as bladder cancer data looms - Investing.com
Wall Street analysts think CG Oncology, Inc. (CGON) could surge 29.78%: Read this before placing a bet - MSN
Will Upcoming Catalysts Reignite CGON's Momentum? - RTTNews
[144] CG Oncology, Inc. SEC Filing - Stock Titan
CGON: Cretostimogene shows durable efficacy and safety in NMIBC, with pivotal data and launch prep ongoing - TradingView
CGON: Cretostimogene shows durable efficacy in NMIBC, with BLA progress and commercial launch preparations advancing - TradingView
Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Did CG Oncology’s Leadership Consolidation Around CEO Kuan Just Shift CGON’s Commercialization Narrative? - Yahoo Finance
CGON stock up 60.8% in six months: Here's what you need to know - MSN
CG Oncology to Present at Upcoming Investor Conferences in June - The Manila Times
CG Oncology CEO joins June fireside chats at Jefferies and Goldman Sachs - Stock Titan
BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $87 - Moomoo
CG Oncology Chief Operating Officer Ambaw Bellete to Depart - Moomoo
CG Oncology, Inc. Announces Chief Commercial Officer Search and Executive Changes in May 2026 8-K Filing - Minichart
CG Oncology (CGON) President & COO to depart as Arthur Kuan named President - Stock Titan
CGON Stock Chart | CG ONCOLOGY INC (NASDAQ:CGON) - ChartMill
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference - MarketBeat
CGON: Cretostimogene advances toward broad NMIBC use with strong data, scalable manufacturing, and launch prep - TradingView
TimesSquare Capital Management LLC Decreases Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
Wolfe Research initiates coverage of CG Oncology (CGON) with peer perform recommendation - MSN
CG Oncology stock initiated at Peerperform by Wolfe Research - Investing.com Nigeria
Public immunotherapy drugmaker, Lyda Hill's investment firm grow at Pegasus Park - The Business Journals
CG Oncology Initiated at Peer Perform by Wolfe Research - Moomoo
CGON Initiated Coverage by Wolfe Research -- Rating: Peer Perfor - GuruFocus
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
SUO-CTC and CG Oncology Announce Award Recipients of the - GlobeNewswire
CG Oncology stock initiated at Peerperform by Wolfe Research By Investing.com - Investing.com South Africa
Wolfe Research Initiates CG Oncology(CGON.US) With Hold Rating - Moomoo
CGON Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):